



NDA 022272/S-042

**SUPPLEMENT APPROVAL**

Purdue Pharma LP  
One Stamford Forum  
Stamford, CT 06901-3431

Attention: Richard J. Fanelli, PhD  
Vice President, R&D and Regulatory Affairs

Dear Dr. Fanelli:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 31, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for OXYCONTIN (oxycodone hydrochloride) Extended-Release Tablets.

This “Changes Being Effected in 30 days” supplemental new drug application provides for minor modifications to the approved risk evaluation and mitigation strategy (REMS).

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for opioid analgesic products intended for use in the outpatient setting (Opioid Analgesic REMS), of which OXYCONTIN is a member, was originally approved on July 9, 2012, and the most recent REMS modification was approved on September 18, 2018. The REMS consists of a Medication Guide, elements to assure safe use, and a timetable for submission of assessments of the REMS.

The proposed modification to the REMS for OXYCONTIN consists of adding a Medication Guide for two authorized generics that are identical to that of the branded product, except that KVK-Tech, Inc. and Rhodes Pharmaceuticals L.P. are listed as distributors for the authorized generics.

Your proposed modified REMS, submitted on January 31, 2019, and appended to this letter, is approved.

This REMS uses a shared system for the elements to assure safe use and the REMS assessments. This shared system, known as the Opioid Analgesic REMS Program, currently includes the products listed on the FDA REMS website, available at <http://www.fda.gov/remis>. Other products may be added in the future if additional Opioid Analgesic NDAs or ANDAs are approved.

The timetable for submission of assessments for the Opioid Analgesic REMS Program remains unchanged.

There are no changes to the REMS assessment plan described in our September 18, 2018, letter.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any of goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication;
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
- c) *If the new indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of the last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing REMS modifications, provide a rationale for why the REMS does not need to be modified.*

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the

submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 022272 REMS CORRESPONDENCE**  
**(insert concise description of content in bold capital letters, e.g.,**  
**UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT**  
**METHODOLOGY**

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered application with elements to assure safe use from using any element to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 022272 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 022272/S-0xx**  
**CHANGES BEING EFFECTED IN 30 DAYS**  
**PROPOSED MINOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR NDA 022272/S-0xx**  
**PRIOR APPROVAL SUPPLEMENT**  
**PROPOSED MAJOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR NDA 022272/S-0xx**  
**PRIOR APPROVAL SUPPLEMENT**  
**PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING**  
**CHANGES SUBMITTED IN SUPPLEMENT XXX**

*or*

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**  
**FOR NDA 022272/S-0xx**  
**REMS ASSESSMENT**  
**PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISIONS FOR NDA 022272**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf> ).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Selma Kraft; Regulatory Project Manager, at (240) 402-9700.

Sincerely,

*{See appended electronic signature page}*

Sharon Hertz, MD  
Director  
Division of Anesthesiology, Addiction Medicine,  
and Pain Medicine  
Office of Neuroscience  
Center for Drug Evaluation and Research

ENCLOSURES:

Medication Guides  
REMS

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

SHARON H HERTZ  
11/14/2019 10:05:18 AM